Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

New Insights in Breast Cancer: Independent Conference Coverage of SABCS 2020

Sara Hurvitz, MD, FACP
Joyce O'Shaughnessy, MD
Released: February 19, 2021
Back Next

References

  1. Johnston SR, Harbeck N, Hegg, R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38:3987-3998.
  2. O'Shaughnessy JA, Johnston S, Harbeck N, et al. Primary outcome analysis of invasive disease-free survival for monarchE: abemaciclib combined with adjuvant endocrine therapy for high risk early breast cancer. Program and abstracts of the 2020 CTRC-AACR San Antonio Breast Cancer Symposium; December 8-11, 2020. Abstract GS1-01.
  3. Loibl S, Marmé F, Martin M, et al. Phase III study of palbociclib combined with endocrine therapy (ET) in patients with hormone-receptor-positive (HR+), HER2-negative primary breast cancer and with high relapse risk after neoadjuvant chemotherapy (NACT): first results from PENELOPE-B. Program and abstracts of the 2020 CTRC-AACR San Antonio Breast Cancer Symposium; December 8-11, 2020. Abstract GS1-02.
  4. Mayer EL, Dueck AC, Martin M, et al. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2021;[Epub ahead of print].
  5. gov. A trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer (NATALEE). Available at: https://clinicaltrials.gov/ct2/show/NCT03701334. Accessed February 8, 2021.
  6. Kunkler IH, Williams LJ, Jack WJ, et al. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol. 2015;16:266-273.
  7. Kunkler IH, Williams LJ, Jack W, et al. Prime 2 randomised trial (postoperative radiotherapy in minimum-risk elderly): Wide local excision and adjuvant hormonal therapy +/- whole breast irradiation in women =/> 65 years with early invasive breast cancer: 10 year results. Program and abstracts of the 2020 CTRC-AACR San Antonio Breast Cancer Symposium; December 8-11, 2020. Abstract GS2-03.
  8. Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004;351:971-977.
  9. Kalinsky K, Barlow WE, Meric-Bernstam F, et al. First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder). Program and abstracts of the 2020 CTRC-AACR San Antonio Breast Cancer Symposium; December 8-11, 2020. Abstract GS3-00.
  10. Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379:111-121.
  11. Cardoso F, van’t Veer LJ, Bogaerts J, et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375:717-729.
  12. Francis PA, Pagani O, Fleming GF, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med. 2018;379:122-137.
  13. Harbeck N, Gluz O, Kuemmel S, et al. Endocrine therapy alone in patients with intermediate or high-risk luminal early breast cancer (0-3 lymph nodes), Recurrence Score <26 and Ki67 response after preoperative endocrine therapy: primary outcome results from the WSG-ADAPT HR+/HER2- trial. Program and abstracts of the 2020 CTRC-AACR San Antonio Breast Cancer Symposium; December 8-11, 2020. Abstract GS4-04.
  14. Sparano J, Crager MR, Tang G, et al. Development and validation of a tool integrating the 21-gene recurrence score and clinicopathlogic features to individualize prognosis for distant recurrence and prediction of absolute chemotherapy benefit in early breast cancer. Program and abstracts of the 2020 CTRC-AACR San Antonio Breast Cancer Symposium; December 8-11, 2020. Abstract GS4-10.
  15. van 't Veer LJ, Cardoso F, Poncet C, et al. How low is low risk: MINDACT updated outcome and treatment benefit in patients considered clinical low risk and stratified by genomic signature, age and nodal status. Program and abstracts of the 2020 CTRC-AACR San Antonio Breast Cancer Symposium; December 8-11, 2020. Abstract GS4-11.
  16. Holmes FA, Moy B, Delaloge S, et al. Continued efficacy of neratinib in patients with HER2-positive early-stage breast cancer: Final overall survival analysis from the randomized phase 3 ExteNET trial. Program and abstracts of the 2020 CTRC-AACR San Antonio Breast Cancer Symposium; December 8-11, 2020. Abstract PD3-03.
  17. Chan A, Moy B, Mansi J, et al. Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase III ExteNET trial. Clin Breast Cancer. 2020;[Epub ahead of print].
  18. Martin M, Holmes FA, Ejlertsen B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1688-1700.
  19. Saura C, Oliveira M, Feng YH, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: phase III NALA trial. J Clin Oncol. 2020;38:3138-3149.
  20. von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380:617-628.
  21. Beckwith H, Schwab R, Yau C, et al. Evaluation of SGN-LIV1a followed by AC in high-risk HER2 negative stage II/III breast cancer: results from the I-SPY 2 trial. Program and abstracts of the 2020 CTRC-AACR San Antonio Breast Cancer Symposium; December 8-11, 2020. Abstract PD1-10.
  22. Han H, Diab S, Alemany C, et al. Open label phase 1b/2 study of ladiratuzumab vedotin in combination with pembrolizumab for first-line treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer. Program and abstracts of the 2019 San Antonio Breast Cancer Symposium; December 10-14, 2019; San Antonio, Texas. Abstract PD1-06.
  23. O’Shaughnessy J, Schwartzberg L, Piccart M, et al. Results from CONTESSA: a phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane. Program and abstracts of the 2020 CTRC-AACR San Antonio Breast Cancer Symposium; December 8-11, 2020. Abstract GS4-01.
  24. Tripathy D, Im SA, Colleoni M, et al. Updated overall survival (OS) results from the phase III MONALEESA-7 trial of pre- or perimenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± Program and abstracts of the 2020 CTRC-AACR San Antonio Breast Cancer Symposium; December 8-11, 2020. Abstract PD1-04.
  25. Im SA, Lu YS, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381:307-316.
  26. Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19:904-915.
  27. Pratt A, Chaudhury A, Solovieff N, et al. Correlative biomarker analysis of intrinsic subtypes and efficacy across the MONALEESA Phase III studies. Program and abstracts of the 2020 CTRC-AACR San Antonio Breast Cancer Symposium; December 8-11, 2020. Abstract GS1-04.
  28. Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29:1541-1547.
  29. Slamon DJ, Neven P, Chia S, et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2020;382:514-524.
  30. Rugo H, Lerebours F, Juric D, et al. Alpelisib + letrozole in patients with PIK3CA-mutated, hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) previously treated with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + fulvestrant: BYLieve study results. Program and abstracts of the 2020 CTRC-AACR San Antonio Breast Cancer Symposium; December 8-11, 2020. Abstract PD2-07.
  31. Andre F, Cireulos E, Rubovszky G, et al. Alpelisib for PIK3CA-mutated, hormone receptor–positive advanced breast cancer. N Engl J Med. 2019;380:1929-1940.
  32. Ciruelos E, Loibl S, Mayer IA, et al. Clinical outcomes of alpelisib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer with PIK3CA alterations detected in plasma ctDNA by next-generation sequencing: Biomarker analysis from the SOLAR-1 study. Program and abstracts of the 2020 CTRC-AACR San Antonio Breast Cancer Symposium; December 8-11, 2020. Abstract PD2-06.
  33. Connolly RM, Zhao F, Miller KD, et al. E2112: randomized phase 3 trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. A trial of the ECOG-ACRIN cancer research group. Program and abstracts of the 2020 CTRC-AACR San Antonio Breast Cancer Symposium; December 8-11, 2020. Abstract GS4-02.
  34. Yardley DA, Ismail-Khan RI, Melichar B, et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol. 2013;31:2128-2135.
  35. Jiang Z, Li W, Hu X, et al. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:806-815.
  36. Morel D, Jeffrey D, Aspeslagh S, et al. Combining epigenetic drugs with other therapies for solid tumours — past lessons and future promise. Nat Rev Clin Oncol. 2020;17:91-107.
  37. Saura C, Ryvo L, Hurvitz S, et al. Impact of neratinib on outcomes in HER2-positive metastatic breast cancer patients with central nervous system disease at baseline: findings from the phase 3 NALA trial. Program and abstracts of the 2020 CTRC-AACR San Antonio Breast Cancer Symposium; December 8-11, 2020. Abstract PD13-09.
  38. Saura C, Oliveira M, Feng YH, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: phase III NALA trial. J Clin Oncol. 2020;38:3138-3149.
  39. Saura C, Oliveira M, Feng YH, et al. Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: findings from the multinational, randomized, phase III NALA trial. Program and abstracts of the 2019 American Society of Clinical Oncology annual meeting; May 31 - June 4, 2019; Chicago, Illinois. Abstr 1002.
  40. US Food and Drug Administration. FDA approves neratinib for metastatic HER2-positive breast cancer. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neratinib-metastatic-her2-positive-breast-cancer. Accessed February 8, 2021.
  41. Hamilton E, Reinisch M, Loi S, et al. Tucatinib vs placebo in combination with trastuzumab and capecitabine for patients with locally advanced unresectable or HER2-positive metastatic breast cancer (HER2CLIMB): Outcomes by hormone receptor status. Program and abstracts of the 2019 American Society of Clinical Oncology annual meeting; May 31 - June 4, 2019; Chicago, Illinois. Abstr PD3-08.
  42. Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382:597-609.
  43. US Food and Drug Administration. FDA approves tucatinib for patients with HER2-positive metastatic breast cancer. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tucatinib-patients-her2-positive-metastatic-breast-cancer. Accessed February 8, 2021.
  44. Wardley A, Mueller V, Paplomata E, et al. Impact of tucatinib on health-related quality of life in patients with HER2+ metastatic breast cancer with stable and active brain metastases. Program and abstracts of the 2020 CTRC-AACR San Antonio Breast Cancer Symposium; December 8-11, 2020. Abstract PD3-08.
  45. Hurvitz S, Vahdat L, Harbeck N, et al. HER2CLIMB-02: a randomized, double-blind, phase 3 study of tucatinib or placebo with T-DM1 for unresectable locally advanced or metastatic HER2+ breast cancer. Program and abstracts of the 2020 CTRC-AACR San Antonio Breast Cancer Symposium; December 8-11, 2020. Abstract OT-28-01.
  46. gov. A study of tucatinib vs. placebo in combination with ado-trastuzumab emtansine (T-DM1) for patients with advanced or metastatic HER2+ breast cancer. Available at: https://clinicaltrials.gov/ct2/show/NCT03975647. Accessed February 8, 2021.
  47. gov. T-DM1 and tucatinib compared with T-DM1 alone in preventing relapses in people with high risk HER2-positive breast cancer, the CompassHER2 RD trial. Available at: https://clinicaltrials.gov/ct2/show/ NCT04457596. Accessed February 8, 2021.
  48. Modi S, Saura C, Yamashita T, et al. Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd) in HER2 positive metastatic breast cancer. Program and abstracts of the 2020 CTRC-AACR San Antonio Breast Cancer Symposium; December 8-11, 2020. Abstract PD3-06.
  49. gov. Neratinib HER mutation basket study (SUMMIT). Available at: https://clinicaltrials.gov/ct2/show/NCT01953926. Accessed February 8, 2021.
  50. Jhaveri K, Saura C, Guerrero-Zotano A, et al. Latest findings from the breast cancer cohort in SUMMIT - a phase 2 ‘basket’ trial of neratinib + trastuzumab + fulvestrant for HER2-mutant, hormone receptor-positive, metastatic breast cancer. Program and abstracts of the 2020 CTRC-AACR San Antonio Breast Cancer Symposium; December 8-11, 2020. Abstract PD1-05.
  51. Ross JS, Wang K, Sheehan CE, et al. Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations. Clin Cancer Res. 2013;19:2668-2676.
  52. Yi Z, Rong G, Guan Y, et al. Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer. NPJ Breast Cancer. 2020;6:59.
  53. Rugo HS, Schmid P, Cescon DW, et al. Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab + chemotherapy versus placebo + chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC). Program and abstracts of the 2020 CTRC-AACR San Antonio Breast Cancer Symposium; December 8-11, 2020. Abstract GS3-01.
  54. Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396:1817-1828.
  55. Pembrolizumab [package insert]. North Wales, PA: Merck Sharpe & Dohme Corp; 2020.
  56. US Food and Drug Administration. FDA grants accelerated approval to pembrolizumab for locally recurrent unresectable or metastatic triple negative breast cancer. Available at: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-pembrolizumab-locally-recurrent-unresectable-or-metastatic-triple. Accessed February 8, 2021.
  57. Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108-2121.
  58. US Food and Drug Administration. FDA approves atezolizumab for PD-L1 positive unresectable locally advanced or metastatic triple-negative breast cancer. Available at: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-atezolizumab-pd-l1-positive-unresectable-locally-advanced-or-metastatic-triple-negative. Accessed February 8, 2021.
  59. Kose MF, Meydanli MM, Tulunay G. Gemcitabine plus carboplatin in platinum-sensitive recurrent ovarian carcinoma. Expert Rev Anticancer Ther. 2006;6:437-443.
  60. Kim SB, Dent R, Im SA, et al. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2017;18:1360-1372.
  61. Dent R, Kim S, Oliveira M, et al. Double-blind placebo (PBO)-controlled randomized phase III trial evaluating first-line ipatasertib (IPAT) combined with paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered locally advanced unresectable or metastatic triple-negative breast cancer (aTNBC): primary results from IPATunity130 cohort A Program and abstracts of the 2020 CTRC-AACR San Antonio Breast Cancer Symposium; December 8-11, 2020. Abstract GS3-04.
  62. Pascual J, Turner NC. Targeting the PI3-kinase pathway in triple-negative breast cancer. Ann Oncol. 2019;30:1051-1060.
  63. Liu Z, Li M, Jiang Z, et al. A comprehensive immunologic portrait of triple-negative breast cancer. Transl Oncol. 2018;11:311-329.
  64. Schmid P, Loirat D, Savas P, et al. Phase Ib study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (TNBC). Programs and abstracts of the 2019 American Association for Cancer Research Annual Meeting; March 29 - April 3, 2019; Atlanta, Georgia. Abstract CT049.
  65. US Food and Drug Administration. FDA grants accelerated approval to sacituzumab govitecan-hziy for metastatic triple negative breast cancer. Available at: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-sacituzumab-govitecan-hziy-metastatic-triple-negative-breast-cancer. Accessed February 8, 2021.
  66. Sacituzumab govitecan-hziy [package insert]. Morris Plains, NJ: Immunomedics, Inc; 2020.
  67. Bardia A, Tolaney SM, Loirat D, et al. A randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC). Programs and abstracts of the 2020 European Society for Medical Oncology Virtual Congress; September 17-21, 2020. Abstract LBA17.
  68. Vidula N, Yau C, Rugo HS. Trop2 gene expression (Trop2e) in primary breast cancer (BC): Correlations with clinical and tumor characteristics. Program and abstracts of the 2017 American Society of Clinical Oncology Annual Meeting; June 2-6, 2017; Chicago, Illinois. Abstract 1075.
  69. Hurvitz SA, Tolaney SM, Punie K, et al. Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Program and abstracts of the 2020 CTRC-AACR San Antonio Breast Cancer Symposium; December 8-11, 2020. Abstract GS3-06.
Back Next
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Novartis Pharmaceuticals Corporation
Puma Biotechnology, Inc.
Seagen Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings